A Phase IIa Pharmacodynamic Study of Antagonism of Irritable Bowel Syndrome (IBS) Symptoms by GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA)
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Emicerfont (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 21 Nov 2009 Results were presented at GASTRO 2009.
- 15 Oct 2008 Actual start date changed from Jul 2006 to Dec 2006 as reported by Clinicaltrials.gov.
- 12 Oct 2008 Phase changed from I/II to II as reported by Clinicaltrials.gov.